Penumbra, Inc.

Penumbra, Inc.

PEN·NYSE

$319.37

+0.20%
HealthcareMedical - Devices

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

At a Glance

Live Snapshot
Market Cap$12.56B
EPS4.5700
P/E Ratio69.88
Earnings Date08/04/2026
9.88%
Return on Invested Capital
2103%
3Y-4009.0%
5Y-462.0%
10Y+17.0%
12.45%
Return on Equity
922%
3Y-6311.0%
5Y-608.0%
10Y+124.0%
9.73%
Return on Assets
964%
3Y-6763.0%
5Y-610.0%
10Y+102.0%
Penumbra, Inc.

Penumbra, Inc. Management Team

PEN · NYSE
ML

Mr. Lambert Shiu

Chief Accounting Officer

Compensation

$581,467

Born 1980(Age 46)
male
MM

Ms. Maggie S. Yuen

Chief Financial Officer

Compensation

$706,796

Born 1972(Age 54)
female
DA

Dr. Arani Bose M.D.

Co-Founder & Director

Compensation

$54,000

Born 1962(Age 64)
MA

Mr. Adam Elsesser J.D.

Co-Founder, Chairman & Chief Executive Officer

Compensation

$630,467

Born 1962(Age 64)
male
MA

Mr. Adam Elsesser J.D.

Co-Founder, Chairman, President & Chief Executive Officer

Compensation

$630,467

Born 1962(Age 64)
male
MP

Mr. Pankaj Tiwari

Executive Vice President & Chief Information Officer

male
MB

Mr. Ben Tompkins

Executive Vice President of Development & Compliance

male
MB

Mr. Ben Sorci

Executive Vice President of Operations

male
MJ

Ms. Johanna Roberts J.D.

Executive Vice President, General Counsel & Secretary

Compensation

$706,467

Born 1972(Age 54)
female
MJ

Ms. Jee Hamlyn-Harris

Investor Relations Officer

female
MS

Ms. Shruthi Narayan

President

Born 1984(Age 42)
female
MS

Ms. Shruthi Narayan

President of Interventional

female
pen

Penumbra, Inc. Insider Positioning

PEN · NYSE

During the last 12 months, insiders have sold $9.61M worth of PEN shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

100

32.82K

Net Activity

-33K

-$33K

3-6 Months

Bought

0

0.00

Sold

4.8K

1.57M

Net Activity

-1.6M

-$1.57M

6-9 Months

Bought

0

0.00

Sold

17.6K

5.19M

Net Activity

-5.2M

-$5.19M

9-12 Months

Bought

0

0.00

Sold

11.4K

2.82M

Net Activity

-2.8M

-$2.82M

Top Buyers

No buying activity

Top Sellers

1
BA

Bose Arani

Director

19.8K shares4 transactions

$5.73M

2
EA

Elsesser Adam

Director, Officer: Ceo

5.8K shares7 transactions

$1.41M

3
YM

Yuen Maggie

Officer: Chief Financial Officer

4.4K shares2 transactions

$1.33M

4
RJ

Roberts Johanna

Officer: Evp, Gen. Counsel & Secretary

2.4K shares8 transactions

$701K

5
GH

Grewal Harpreet

Director

844 shares5 transactions

$230K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $9.61M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$33K

Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.

Insider Participation

High Selling

5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

Insider Activity Insight

Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.

SEC Filings

PEN - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2026

N/A

April 29, 2026
June 18, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 16, 2025
May 28, 2025
2025
DEF 14A

DEF 14A 2024

N/A

April 24, 2024
June 05, 2024
2024
DEF 14A

DEF 14A

N/A

April 19, 2023
April 19, 2023
 
DEF 14A

DEF 14A 2022

N/A

April 20, 2022
June 01, 2022
2022
DEF 14A

DEF 14A 2021

N/A

April 22, 2021
June 02, 2021
2021
DEF 14A

DEF 14A 2020

N/A

April 23, 2020
June 03, 2020
2020
DEF 14A

DEF 14A 2018

N/A

April 26, 2019
December 31, 2018
2018
DEF 14A

DEF 14A 2018

N/A

April 25, 2018
June 06, 2018
2018
DEF 14A

DEF 14A 2017

N/A

April 25, 2017
April 25, 2017
2017
Showing 1 to 10 of 11 filings